Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Examining clonal, cell hierarchy and immune microenvironment dynamics in acute myeloid leukemia

EF 2023-24

Résumé
Acute myeloid leukemia (AML) is an aggressive form of blood cancer with a low survival rate and a high occurrence of relapse. Current genetic approaches for risk stratification have proven inaccurate for many patients, indicating that the mechanisms behind treatment resistance and relapse do not rely simply on genetics, but additional factors as well. Supportive of this, both leukemic cellular hierarchy composition and the immune microenvironment have recently been implicated with survival and treatment outcomes. However, studies examining these two disease hallmarks in the context of relapse have been limited. This proposal aims to provide a comprehensive analysis of the clonal, cell hierarchy and immune dynamics of AML from diagnosis to relapse. Firstly, the clonal, hierarchy and immune cell composition of over 100 paired patient diagnosis and relapse samples will be determined through bioinformatic analysis. Secondly, dynamics in these three regards from diagnosis to relapse will be determined and correlated with time to relapse and survival outcomes. Finally, patient groups with either similar clonal, hierarchy and immune cell composition at diagnosis, or that evolve similarly in these regards from diagnosis to relapse, will be identified. Together, these analyses will shed light on the mechanisms behind treatment resistance, identify new prognostic dynamic biomarkers, and potentially identify novel AML subgroups with distinct biological characteristics. Such findings would be informative to both current patient treatment, and the development of new therapies to target treatment-resistant leukemic cells.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506291
Name
Stephenson Maria R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining clonal, cell hierarchy and immune microenvironment dynamics in acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cell Hierarchy; Genomics; Immune Microenvironment; Leukemia; Relapse; Transcriptomics
Abstract
Acute myeloid leukemia (AML) is an aggressive form of blood cancer with a low survival rate and a high occurrence of relapse. Current genetic approaches for risk stratification have proven inaccurate for many patients, indicating that the mechanisms behind treatment resistance and relapse do not rely simply on genetics, but additional factors as well. Supportive of this, both leukemic cellular hierarchy composition and the immune microenvironment have recently been implicated with survival and treatment outcomes. However, studies examining these two disease hallmarks in the context of relapse have been limited. This proposal aims to provide a comprehensive analysis of the clonal, cell hierarchy and immune dynamics of AML from diagnosis to relapse. Firstly, the clonal, hierarchy and immune cell composition of over 100 paired patient diagnosis and relapse samples will be determined through bioinformatic analysis. Secondly, dynamics in these three regards from diagnosis to relapse will be determined and correlated with time to relapse and survival outcomes. Finally, patient groups with either similar clonal, hierarchy and immune cell composition at diagnosis, or that evolve similarly in these regards from diagnosis to relapse, will be identified. Together, these analyses will shed light on the mechanisms behind treatment resistance, identify new prognostic dynamic biomarkers, and potentially identify novel AML subgroups with distinct biological characteristics. Such findings would be informative to both current patient treatment, and the development of new therapies to target treatment-resistant leukemic cells.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stephenson, Maria R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~